The Senescence Program is Reduced in Proteasome Inhibitor Bortezomib-Resistant PC3 Prostate Cancer Cell Line
Objective: Senescence may act as an antitumor mechanism by preventing the proliferation of cancer cells. Here we investigated the hypothesis that PC3 prostate cancer cells resistant to bortezomib respond differently to proteasomal inhibition with respect to induction of the senescence program as com...
Saved in:
| Main Authors: | Ertan Kanbur, Semih Şeker, Ferah Budak, Azmi Yerlikaya |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2023-06-01
|
| Series: | European Journal of Biology |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/B218A92BA9454949935DB450BDB7C8DC |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01) -
The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells
by: Georgios Kalampounias, et al.
Published: (2025-05-01) -
Clinical use and toxicities of bortezomib in pediatric patients: a systematic review
by: Zachary C. LeBlanc, et al.
Published: (2025-08-01) -
Targeted Delivery of Bortezomib Using Retinoid-Based Nanoparticle: Modulating Liver Fibrosis through the TGF-β1/Smad3 Pathway
by: Samaneh Siapoush, et al.
Published: (2025-04-01)